The Meals and Drug Administration (FDA) has accepted Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, remedy of adults with cutaneous squamous cell...
The U.S. Meals and Drug Administration (FDA) has granted quick monitor designation to UB-VV111 for the remedy of relapsed/refractory giant B-cell lymphoma...
